Cargando…

Estradiol and intrauterine device treatment for moderate and severe intrauterine adhesions after transcervical resection

OBJECTIVE: To explore the effect of 4 mg/day, 6 mg/day, and 8 mg/day estradiol alone or in combination with an intrauterine device (IUD) in patients with moderate and severe intrauterine adhesion (IUA) after transcervical resection of adhesion (TCRA). METHODS: Patients with moderate or severe IUA wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yun, Chen, Xiuying, Qian, Zhida, Cao, Lili, Zhan, Sifeng, Huang, Lili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422139/
https://www.ncbi.nlm.nih.gov/pubmed/36038909
http://dx.doi.org/10.1186/s12905-022-01940-6
_version_ 1784777748797980672
author Sun, Yun
Chen, Xiuying
Qian, Zhida
Cao, Lili
Zhan, Sifeng
Huang, Lili
author_facet Sun, Yun
Chen, Xiuying
Qian, Zhida
Cao, Lili
Zhan, Sifeng
Huang, Lili
author_sort Sun, Yun
collection PubMed
description OBJECTIVE: To explore the effect of 4 mg/day, 6 mg/day, and 8 mg/day estradiol alone or in combination with an intrauterine device (IUD) in patients with moderate and severe intrauterine adhesion (IUA) after transcervical resection of adhesion (TCRA). METHODS: Patients with moderate or severe IUA who reived 4 mg/day, 6 mg/day, and 8 mg/day estradiol alone or in combination with an intrauterine device (IUD) after TCRA in Women’s Hospital, Zhejiang University School of Medicine, from March 2014 to December 2014 were enrolled in this retrospective case–control study. In group A, 14 patients received estradiol 4 mg/day + IUD after the first operation; in group B, 29 patients (group B0) received estradiol 6 mg/day after the first operation, and 73 patients (group B1) received estradiol 6 mg/day + IUD; in group C, 14 patients received estradiol 8 mg/day + IUD after the first operation. Referring to ESGE's IUA diagnostic classification method, 72 patients had moderate adhesion, and 58 cases had severe adhesion. Outpatient follow-up was performed at 1 and 23 months and after 1 year. The postoperative menstrual improvement, uterine cavity recovery, drug side effects at two to three months, and pregnancy situation at one year were recorded. RESULTS: There were no significant differences in age, BMI, and previous intrauterine operation times between the 3 groups (all p > 0.05). Compared with Group A, more patients in group C had severe IUA (p = 0.008). In addition, there were no differences in menstrual recovery, uterine cavity recovery, and pregnancy in one year between the 3 groups (p > 0.05) and between groups B(0) and B(1) (p > 0.05). In group B1, 51 (69.86%) patients had IUD incarceration. CONCLUSION: This data suggests that 4 mg/d doses of estrogen may have the same effect in improving the menstrual condition, uterine cavity morphology, and reproductive ability compared to a higher dosage (6 mg/day estrogen and 8 mg/day). In addition, the placement of IUD in the uterine cavity during TCRA may cause IUD incarceration, and the treatment results for the prevention of IUA are not better than without IUD.
format Online
Article
Text
id pubmed-9422139
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94221392022-08-30 Estradiol and intrauterine device treatment for moderate and severe intrauterine adhesions after transcervical resection Sun, Yun Chen, Xiuying Qian, Zhida Cao, Lili Zhan, Sifeng Huang, Lili BMC Womens Health Research OBJECTIVE: To explore the effect of 4 mg/day, 6 mg/day, and 8 mg/day estradiol alone or in combination with an intrauterine device (IUD) in patients with moderate and severe intrauterine adhesion (IUA) after transcervical resection of adhesion (TCRA). METHODS: Patients with moderate or severe IUA who reived 4 mg/day, 6 mg/day, and 8 mg/day estradiol alone or in combination with an intrauterine device (IUD) after TCRA in Women’s Hospital, Zhejiang University School of Medicine, from March 2014 to December 2014 were enrolled in this retrospective case–control study. In group A, 14 patients received estradiol 4 mg/day + IUD after the first operation; in group B, 29 patients (group B0) received estradiol 6 mg/day after the first operation, and 73 patients (group B1) received estradiol 6 mg/day + IUD; in group C, 14 patients received estradiol 8 mg/day + IUD after the first operation. Referring to ESGE's IUA diagnostic classification method, 72 patients had moderate adhesion, and 58 cases had severe adhesion. Outpatient follow-up was performed at 1 and 23 months and after 1 year. The postoperative menstrual improvement, uterine cavity recovery, drug side effects at two to three months, and pregnancy situation at one year were recorded. RESULTS: There were no significant differences in age, BMI, and previous intrauterine operation times between the 3 groups (all p > 0.05). Compared with Group A, more patients in group C had severe IUA (p = 0.008). In addition, there were no differences in menstrual recovery, uterine cavity recovery, and pregnancy in one year between the 3 groups (p > 0.05) and between groups B(0) and B(1) (p > 0.05). In group B1, 51 (69.86%) patients had IUD incarceration. CONCLUSION: This data suggests that 4 mg/d doses of estrogen may have the same effect in improving the menstrual condition, uterine cavity morphology, and reproductive ability compared to a higher dosage (6 mg/day estrogen and 8 mg/day). In addition, the placement of IUD in the uterine cavity during TCRA may cause IUD incarceration, and the treatment results for the prevention of IUA are not better than without IUD. BioMed Central 2022-08-29 /pmc/articles/PMC9422139/ /pubmed/36038909 http://dx.doi.org/10.1186/s12905-022-01940-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Sun, Yun
Chen, Xiuying
Qian, Zhida
Cao, Lili
Zhan, Sifeng
Huang, Lili
Estradiol and intrauterine device treatment for moderate and severe intrauterine adhesions after transcervical resection
title Estradiol and intrauterine device treatment for moderate and severe intrauterine adhesions after transcervical resection
title_full Estradiol and intrauterine device treatment for moderate and severe intrauterine adhesions after transcervical resection
title_fullStr Estradiol and intrauterine device treatment for moderate and severe intrauterine adhesions after transcervical resection
title_full_unstemmed Estradiol and intrauterine device treatment for moderate and severe intrauterine adhesions after transcervical resection
title_short Estradiol and intrauterine device treatment for moderate and severe intrauterine adhesions after transcervical resection
title_sort estradiol and intrauterine device treatment for moderate and severe intrauterine adhesions after transcervical resection
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422139/
https://www.ncbi.nlm.nih.gov/pubmed/36038909
http://dx.doi.org/10.1186/s12905-022-01940-6
work_keys_str_mv AT sunyun estradiolandintrauterinedevicetreatmentformoderateandsevereintrauterineadhesionsaftertranscervicalresection
AT chenxiuying estradiolandintrauterinedevicetreatmentformoderateandsevereintrauterineadhesionsaftertranscervicalresection
AT qianzhida estradiolandintrauterinedevicetreatmentformoderateandsevereintrauterineadhesionsaftertranscervicalresection
AT caolili estradiolandintrauterinedevicetreatmentformoderateandsevereintrauterineadhesionsaftertranscervicalresection
AT zhansifeng estradiolandintrauterinedevicetreatmentformoderateandsevereintrauterineadhesionsaftertranscervicalresection
AT huanglili estradiolandintrauterinedevicetreatmentformoderateandsevereintrauterineadhesionsaftertranscervicalresection